Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19

Effective agents to treat coronavirus infection are urgently required, not only to treat COVID-19, but to prepare for future outbreaks. Repurposed anti-virals such as remdesivir and human anti-inflammatories such as barcitinib have received emergency approval but their overall benefits remain unclea...

Descripción completa

Detalles Bibliográficos
Autores principales: Redhead, Martin A., Owen, C. David, Brewitz, Lennart, Collette, Amelia H., Lukacik, Petra, Strain-Damerell, Claire, Robinson, Sean W., Collins, Patrick M., Schäfer, Philipp, Swindells, Mark, Radoux, Chris J., Hopkins, Iva Navratilova, Fearon, Daren, Douangamath, Alice, von Delft, Frank, Malla, Tika R., Vangeel, Laura, Vercruysse, Thomas, Thibaut, Jan, Leyssen, Pieter, Nguyen, Tu-Trinh, Hull, Mitchell, Tumber, Anthony, Hallett, David J., Schofield, Christopher J., Stuart, David I., Hopkins, Andrew L., Walsh, Martin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225628/
https://www.ncbi.nlm.nih.gov/pubmed/34168183
http://dx.doi.org/10.1038/s41598-021-92416-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225628/
https://www.ncbi.nlm.nih.gov/pubmed/34168183
http://dx.doi.org/10.1038/s41598-021-92416-4

Ejemplares similares